ES2121084T3 - Utilizacion de derivados de terfenadina como antihistaminicos en un paciente que padece de trastornos hepaticos. - Google Patents

Utilizacion de derivados de terfenadina como antihistaminicos en un paciente que padece de trastornos hepaticos.

Info

Publication number
ES2121084T3
ES2121084T3 ES93909249T ES93909249T ES2121084T3 ES 2121084 T3 ES2121084 T3 ES 2121084T3 ES 93909249 T ES93909249 T ES 93909249T ES 93909249 T ES93909249 T ES 93909249T ES 2121084 T3 ES2121084 T3 ES 2121084T3
Authority
ES
Spain
Prior art keywords
patient
hydrogen
antihistaminics
hepatic disorders
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93909249T
Other languages
English (en)
Inventor
James K Woodward
Richard R Okerholm
Mark G Eller
Bruce E Mcnutt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27128589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2121084(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2121084T3 publication Critical patent/ES2121084T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN METODO PARA PROPORCIONAR UN EFECTO ANTIHISTAMINICO EN UN PACIENTE DAÑADO HEPATICAMENTE QUE LO NECESITE, Y QUE CONSISTE EN ADMINISTRAR A DICHO PACIENTE UNA CANTIDAD ANTIHISTAMINICA EFECTIVA DE UN COMPUESTO DE LA FORMULA (I) EN LA QUE R1 ES HIDROGENO O HIDROXI; R2 ES HIDROGENO; O R1 Y R2 JUNTOS FORMAN UN SEGUNDO ENLACE ENTRE LOS ATOMOS DE CARBONO QUE LLEVAN R1 Y R2; N ES UN ENTRE DE 1 A 5; R3 ES -COOH O -COOALKILO EN DONDE LA UNIDAD DE ALKILO TIENE DE 1 A 6 ATOMOS DE CARBONO Y ES DE CADENA RECTA O RAMIFICADA; CADA A Y B ES HIDROGENO O HIDROXI SIEMPRE Y CUANDO AL MENOS UNO DE ENTRE A Y B SEA HIDROGENO; O UNA SAL FARMACEUTICAMENTE ACEPTABLE E ISOMEROS INDIVIDUALES DEL MISMO.
ES93909249T 1992-05-11 1993-04-06 Utilizacion de derivados de terfenadina como antihistaminicos en un paciente que padece de trastornos hepaticos. Expired - Lifetime ES2121084T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88080192A 1992-05-11 1992-05-11
US92289092A 1992-07-31 1992-07-31

Publications (1)

Publication Number Publication Date
ES2121084T3 true ES2121084T3 (es) 2002-02-16

Family

ID=27128589

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93909249T Expired - Lifetime ES2121084T3 (es) 1992-05-11 1993-04-06 Utilizacion de derivados de terfenadina como antihistaminicos en un paciente que padece de trastornos hepaticos.

Country Status (16)

Country Link
US (7) US6037353A (es)
EP (1) EP0639976B1 (es)
JP (1) JPH07506828A (es)
KR (1) KR950701525A (es)
AT (1) ATE194913T1 (es)
AU (1) AU679910B2 (es)
CA (1) CA2134211C (es)
CL (1) CL2004000304A1 (es)
DE (1) DE69320952T2 (es)
DK (1) DK0639976T3 (es)
ES (1) ES2121084T3 (es)
HU (1) HU223774B1 (es)
MX (1) MX9302704A (es)
NO (1) NO307688B1 (es)
NZ (1) NZ251834A (es)
WO (1) WO1993023047A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023047A1 (en) * 1992-05-11 1993-11-25 Merrell Dow Pharmaceuticals Inc. Use of terfenadine derivatives as antihistaminics in a hepatically impaired patient
FI950467A7 (fi) † 1992-08-03 1995-03-31 Sepracor Inc Terfenadiinin metaboliitit ja niiden optisesti puhtaat isomeerit aller gisten sairauksien hoitamiseksi
WO1995010278A1 (en) * 1993-10-15 1995-04-20 Hoechst Marion Roussel, Inc. Treatment of allergic disorders with terfenadine carboxylate
IT1271417B (it) * 1993-10-15 1997-05-28 Erregierre Ind Chim Composti ad attivita' antiistaminica procedimento per la loro preperazione e composizioni farmaceutiche che li contengono.
CA2449419C (en) 1994-05-18 2011-09-06 Aventis Pharmaceuticals Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
US20030045722A1 (en) * 1994-05-18 2003-03-06 Henton Daniel R. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
EP0812195B1 (en) 1995-02-28 2002-10-30 Aventis Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol compounds
NZ501248A (en) * 1997-08-26 2001-06-29 Aventis Pharma Inc Pharmaceutical composition for combination of piperidinoalkanol-decongestant
US6194431B1 (en) 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
US20030021849A1 (en) * 2001-04-09 2003-01-30 Ben-Zion Dolitzky Polymorphs of fexofenadine hydrochloride
CZ20033019A3 (cs) * 2001-04-09 2004-07-14 Teva Pharmaceutical Industries Ltd. Polymorfní formy chloridu fexofenadinu
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
EP1474392A1 (en) * 2002-06-10 2004-11-10 Teva Pharmaceutical Industries Ltd. Polymorphic form xvi of fexofenadine hydrochloride
EP1393728A1 (en) * 2002-08-30 2004-03-03 Vrije Universiteit Inverse agonists acting at virus-encoded G protein-coupled receptors
US20050065183A1 (en) * 2003-07-31 2005-03-24 Indranil Nandi Fexofenadine composition and process for preparing
KR20070007196A (ko) * 2004-04-26 2007-01-12 테바 파마슈티컬 인더스트리즈 리미티드 펙소페나딘 히드로클로라이드의 결정형 및 이의 제조 방법
JP2008514641A (ja) * 2004-09-28 2008-05-08 テバ ファーマシューティカル インダストリーズ リミティド 結晶形フェキソフェナジン、およびその調製方法
US20090076080A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched fexofenadine
EP2288355A1 (en) * 2008-05-30 2011-03-02 Fairfield Clinical Trials LLC Method and composition for skin inflammation and discoloration

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4285958A (en) * 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkylene ketones, pharmaceutical compositions thereof and method of use thereof
AR240018A1 (es) * 1987-10-07 1990-01-31 Merrell Pharma Inc Procedimiento para preparar una composicion que comprende derivados de piperidinoalcanol.
US4929605A (en) * 1987-10-07 1990-05-29 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol derivatives
WO1993023047A1 (en) * 1992-05-11 1993-11-25 Merrell Dow Pharmaceuticals Inc. Use of terfenadine derivatives as antihistaminics in a hepatically impaired patient
FI950467A7 (fi) * 1992-08-03 1995-03-31 Sepracor Inc Terfenadiinin metaboliitit ja niiden optisesti puhtaat isomeerit aller gisten sairauksien hoitamiseksi

Also Published As

Publication number Publication date
US6187791B1 (en) 2001-02-13
NO307688B1 (no) 2000-05-15
US20030130315A1 (en) 2003-07-10
HU223774B1 (hu) 2005-01-28
EP0639976A1 (en) 1995-03-01
WO1993023047A1 (en) 1993-11-25
CA2134211A1 (en) 1993-11-25
DK0639976T3 (da) 1999-02-15
NO944287D0 (no) 1994-11-10
NO944287L (no) 1994-11-10
KR950701525A (ko) 1995-04-28
AU679910B2 (en) 1997-07-17
US6399632B1 (en) 2002-06-04
CA2134211C (en) 1999-06-29
NZ251834A (en) 1997-07-27
US20030055083A1 (en) 2003-03-20
US20060205782A1 (en) 2006-09-14
US6037353A (en) 2000-03-14
HUT71402A (en) 1995-11-28
DE69320952T2 (de) 1999-05-27
DE69320952D1 (de) 1998-10-15
ATE194913T1 (de) 2000-08-15
AU3973493A (en) 1993-12-13
US20100168166A1 (en) 2010-07-01
MX9302704A (es) 1994-06-30
EP0639976B1 (en) 2000-07-26
CL2004000304A1 (es) 2005-05-27
JPH07506828A (ja) 1995-07-27

Similar Documents

Publication Publication Date Title
HUT71402A (en) Use of terfenadine derivatives as antihistaminics in a hepatically impaired patient
FI956248A0 (fi) Uusia välituotteita antihistamiinisten 4-difenyylimetyyli/difenyylimetoksipiperidiinijohdannaisten valmistusta varten
SE8002634L (sv) Piperidinderivat
ES2091057T3 (es) Composicion medicinal que mejora el metabolismo de los lipidos.
ES2148305T3 (es) Derivados de aminoacidos ciclicos que tienen actividad inhibidora de ace y nep.
DE69315827D1 (de) Neue acylierte phospholipid-arzneimittel
TR199902350T2 (xx) Yeni piridin t�revleri ve onlardan olu�an farmakotik bile�imler.
ES2055235T3 (es) Composicion anti-inflamatoria y/o antialergica que comprende derivados de glutation.
ATE172959T1 (de) Acylphenylglycin-derivat und dieses als aktivbestandteil enthaltendes vorbeugungs -und heilmittel gegen durch erhöhte collagenaseaktivität verursachte krankheiten
HN1999000026A (es) Biciclo (2.2.1) heptanos y compuestos relacionados.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 639976

Country of ref document: ES

FG2A Definitive protection

Ref document number: 639976

Country of ref document: ES